Trout Harry R. III's Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Dec 3, 2025
- Accession no.
- 0002064832-25-000050
- Filed
- Dec 3, 2025
- Trade date
- Dec 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $5.30K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trout Harry R. IIICIK 0002085123 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | Common Stock | FTax withholdingDisposed | −105 | $14.12 | −$1,482.6 | 17,270 | Direct | |
| Dec 2, 2025 | Common Stock | SSaleDisposed | −380 | $13.96 | −$5,304.8 | 16,890 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Vice President, Finance (Principal Financial Officer)